Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival

Cancer Science

Volumn 106, Issue 3, 2015, Pages 262-269

  Desurmont, Thibault ^a,b   Skrypek, Nicolas ^a   Duhamel, Alain ^a   Jonckheere, Nicolas ^a   Millet, Guillaume ^a,c   Leteurtre, Emmanuelle ^a,c   Gosset, Pierre ^b   Duchene, Belinda ^a   Ramdane, Nassima ^a   Hebbar, Mohamed ^a,c   Van Seuningen, Isabelle ^a   Pruvot, François René ^c   Huet, Guillemette ^a,c   Truant, Stéphanie ^a,c  

^a UNIV LILLE   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

5FU based chemotherapy; Colorectal cancer; CXCL7; CXCR2; Liver metastasis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CHEMOKINE; CHEMOKINE CXCL7; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BETA THROMBOGLOBULIN; CAMPTOTHECIN; CXCR4 PROTEIN, HUMAN; DEOXYCYTIDINE; PLATINUM COMPLEX; PPBP PROTEIN, HUMAN;

ADULT; AGGRESSIVENESS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; COLON CANCER; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COLONIC NEOPLASMS; GENETICS; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA-THROMBOGLOBULIN; CAMPTOTHECIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; RECEPTORS, CXCR4; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION;

EID: 84925808569     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12603     Document Type: Article

References (44)

1. Majek O, Gondos A, Jansen L et al. Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer 2012; 106: 1875-80.
2. Rees JR, Blazeby JM, Fayers P et al. Patient-reported outcomes after hepatic resection of colorectal cancer metastases. J Clin Oncol 2012; 30: 1364-70.
3. Chan KM, Chiang JM, Lee CF et al. Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment. World J Surg Oncol 2011; 9: 174.
4. Andreou A, Aloia TA, Brouquet A, Vauthey JN. Recent advances in the curative treatment of colorectal liver metastases. Gastrointest Cancer Res 2011; 4: S2-8.
5. Sorbye H, Mauer M, Gruenberger T et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 2012; 255: 534-9.
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
7. Dessein AF, Stechly L, Jonckheere N et al. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res 2010; 70: 4644-54.
8. Oladipo O, Conlon S, O'Grady A et al. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer 2011; 104: 480-7.
9. Verbeke H, Struyf S, Laureys G, Van Damme J. The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev 2011; 22: 345-58.
10. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-31.
11. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
12. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-44.
13. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104: 550-7.
14. Kim J, Takeuchi H, Lam ST et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23: 2744-53.
15. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-7.
16. Terada H, Urano T, Konno H. Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res 2005; 37: 166-72.
17. Rubie C, Frick VO, Pfeil S et al. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol 2007; 13: 4996-5002.
18. Lee YS, Choi I, Ning Y et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 2012; 106: 1833-41.
19. Strieter RM, Polverini PJ, Kunkel SL et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-57.
20. Heidemann J, Ogawa H, Dwinell MB et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2003; 278: 8508-15.
21. Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol 2011; 22: 2267-76.
22. Matsubara J, Honda K, Ono M et al. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 160-71.
23. Van Seuningen I, Perrais M, Pigny P, Porchet N, Aubert JP. Sequence of the 5'-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells. Biochem J 2000; 348(Pt 3): 675-86.
24. Skrypek N, Duchene B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene 2013; 32: 1714-23.
25. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-16.
26. Klinger M, Eipeldauer S, Hacker S et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009; 35: 515-20.
27. Millet G, Truant S, Leteurtre E et al. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. Ann Surg 2012; 256: 755-61; discussion 61-2.
28. Mitry E, Fields AL, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-11.
29. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
30. Ning Y, Labonte MJ, Zhang W et al. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther 2012; 11: 1353-64.
31. Ning Y, Manegold PC, Hong YK et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 2011; 128: 2038-49.
32. Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 2006; 66: 3071-7.
33. Jamieson T, Clarke M, Steele CW et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 2012; 122: 3127-44.
34. Tazzyman S, Barry ST, Ashton S et al. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer 2011; 129: 847-58.
35. Addison CL, Daniel TO, Burdick MD et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000; 165: 5269-77.
36. Ijichi H, Chytil A, Gorska AE et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 2011; 121: 4106-17.
37. Asfaha S, Dubeykovskiy AN, Tomita H et al. Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology 2013; 144: 155-66.
38. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593-609.
39. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006; 42: 768-78.
40. Tang Z, Yu M, Miller F, Berk RS, Tromp G, Kosir MA. Increased invasion through basement membrane by CXCL7-transfected breast cells. Am J Surg 2008; 196: 690-6.
41. Yu M, Berk R, Kosir MA. CXCL7-mediated stimulation of lymphangiogenic factors VEGF-C, VEGF-D in human breast cancer cells. J Oncol 2010; 2010: 939407.
42. Liu S, Ginestier C, Ou SJ et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71: 614?24.
43. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
44. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 2011; 17: 5850-7.